Complement regulates TLR2/6 and TLR9 activation. (A) ELISA assays of plasma IL-6 levels in wild-type (WT) and DAF^−/− mice after zymosan treatment. (B) ELISA assays of plasma IL-6 and IL-12p40 levels in WT and MyD88^−/− mice 3 hours after zymosan or zymosan/CVF treatment. (C) ELISA assays of plasma IL-6 and IL-12p40 levels in WT, DAF^−/−, DAF^−/−/C3^−/−, and DAF^−/−/C5aR^−/− mice 3 hours after CpG treatment. (D) ELISA assays of plasma IL-6 and IL-12p40 levels in WT mice 3 hours after CpG, CVF, or CpG/CVF treatment. (E) ELISA assays of plasma IL-12p40 levels in WT, C5aR^−/−, and C3aR^−/− mice 3 hours after CpG or CpG/CVF treatment. Two mice were in the MyD88^−/− groups in panel B; 4 to 7 mice were in all other groups. Values shown are the mean (± SEM). *P < .05, **P < .001, Student t test.